NOVN.CH

129.68

+0.42%↑

LONN.CH

526.6

+0.15%↑

STMN.CH

92.52

+1.54%↑

NOVN.CH

129.68

+0.42%↑

LONN.CH

526.6

+0.15%↑

STMN.CH

92.52

+1.54%↑

NOVN.CH

129.68

+0.42%↑

LONN.CH

526.6

+0.15%↑

STMN.CH

92.52

+1.54%↑

NOVN.CH

129.68

+0.42%↑

LONN.CH

526.6

+0.15%↑

STMN.CH

92.52

+1.54%↑

NOVN.CH

129.68

+0.42%↑

LONN.CH

526.6

+0.15%↑

STMN.CH

92.52

+1.54%↑

Inicio・Lista de Acciones・Roche Holding AG

Roche Holding AG

Cerrado

SectorSanidad

374.4 -2.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

373.6

Máximo

382.6

Métricas clave
By Trading Economics
Ingresos	1.8B 5.5B
Ventas	15B 31B
P/B Media del Sector	23.748 108.767
Rentabilidad por dividendo	2.59
Margen de beneficios	17.892
Empleados	103,249
EBITDA	5.1B 12B

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	2.59% 2.21%

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	15B 303B
Apertura anterior	376.54
Cierre anterior	374.4

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

11 / 351 Clasificación en Healthcare

Roche Holding AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 ene 2026, 10:07 UTC

Ganancias

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 ene 2026, 07:07 UTC

Ganancias

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 nov 2025, 11:04 UTC

Principales Movimientos del Mercado

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 oct 2025, 09:32 UTC

Ganancias

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 oct 2025, 05:54 UTC

Ganancias

Roche Raises Full-Year Earnings Outlook

29 ene 2026, 11:40 UTC

Charlas de Mercado

Ganancias

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 ene 2026, 06:05 UTC

Ganancias

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 ene 2026, 06:04 UTC

Ganancias

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 ene 2026, 06:03 UTC

Ganancias

Roche Issues 2026 View

29 ene 2026, 06:02 UTC

Ganancias

Analysts Saw 2025 Core EPS at CHF19.70

29 ene 2026, 06:02 UTC

Ganancias

Roche: 2025 Core EPS CHF19.46

29 ene 2026, 06:01 UTC

Ganancias

Analysts Had Seen 2025 Sales At CHF61.47B

29 ene 2026, 06:01 UTC

Ganancias

Roche 2025 Sales CHF61.52B

28 ene 2026, 11:22 UTC

Ganancias

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 ene 2026, 11:31 UTC

Charlas de Mercado

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 ene 2026, 11:24 UTC

Charlas de Mercado

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 ene 2026, 09:30 UTC

Charlas de Mercado

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 ene 2026, 07:52 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Roche Obesity Study Data Look Encouraging -- Market Talk

16 ene 2026, 17:03 UTC

Charlas de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 ene 2026, 14:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Pharma Sector Can Spend Big on M&A -- Market Talk

22 dic 2025, 08:48 UTC

Charlas de Mercado

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 nov 2025, 12:47 UTC

Charlas de Mercado

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 nov 2025, 12:16 UTC

Charlas de Mercado

Ganancias

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 oct 2025, 09:19 UTC

Charlas de Mercado

Ganancias

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 oct 2025, 09:11 UTC

Charlas de Mercado

Ganancias

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 oct 2025, 05:09 UTC

Ganancias

Roche 3Q Sales Up 6% At CER

23 oct 2025, 05:07 UTC

Ganancias

Roche 3Q Sales CHF14.92B

23 oct 2025, 05:07 UTC

Ganancias

Analysts Had Seen 3Q Sales At CHF15.17B

23 oct 2025, 05:07 UTC

Ganancias

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 oct 2025, 05:05 UTC

Ganancias

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

Comparación entre iguales

Cambio de precio

Roche Holding AG previsión

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Roche Holding AG Dist en los últimos 3 meses.

Sentimiento

By Acuity

11 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.